Navigation Links
Inverness - Chemogen Establish Exclusive License for TB Antibodies
Date:11/8/2007

WALTHAM, Mass., Nov. 8 /PRNewswire-FirstCall/ -- Inverness Medical Innovations (Amex: IMA) today announced that it has entered into an agreement with Chemogen, Inc. for the worldwide manufacture and distribution of tests for the rapid detection of Mycobacterium, the primary causative agent of tuberculosis. The tests will utilize Chemogen's proprietary antibodies for the detection of Lipoarabinomannan (LAM) antigen in urine as an aid in the diagnosis of current mycobacterial infection (including Tuberculosis), especially in those patients who are HIV positive.

Commenting on the agreement, Ron Zwanziger, CEO of Inverness, said, "HIV is driving a deadly resurgence of TB on a global scale, claiming nearly 2 million lives annually in recent years. The need for reliable TB diagnosis in HIV co-infected populations has become a top priority, especially in the developing world where these two pandemics are taking a devastating toll on human populations. Inverness is already a leading provider of rapid HIV diagnostic tests to these areas and the availability of a reliable test that can diagnose tuberculosis in HIV-infected patients will be a major step forward in the control of the disease."

In addition to the immediate launch of an already developed and highly sensitive ELISA test to endemic regions, Inverness plans to complete the development of a rapid point of care assay that will reliably and rapidly detect LAM in urine samples, using its proprietary lateral flow technology.

About Inverness

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts. For additional information on Inverness Medical Innovations, please visit http://www.invernessmedical.com.

About Chemogen

Chemogen is an emerging biotechnology company focused on the development and commercialization of novel and proprietary technology for the rapid diagnosis of infectious diseases.

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding possible margin improvements. Actual results may differ materially due to numerous factors, including without limitation, the ability of Inverness to develop and commercialize new products and obtain regulatory approvals; the ability of Inverness to successfully and efficiently manufacture products; future demand for and costs of the Inverness' products; and the risks and uncertainties described in Inverness' periodic reports filed with the Securities and Exchange Commission under the federal securities laws, including Inverness' Annual Report on Form 10-K for the year ended December 31, 2006, as amended. Inverness undertakes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Inverness Medical Innovations
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
4. European Centre for Modern Drug Discovery Established in Hamburg
5. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
6. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
7. KGI and Smith College Establish Leadership Forum for Women in Bioscience
8. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
9. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
10. Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
Breaking Biology News(10 mins):